RCUR-SMP

N/A

Report date: 2025/01/26 16:07:49
NME

Base Information

Drug NameRCUR-SMP
Drug Alias Nameanti-SCN2A antisense oligonucleotide (RogCon/Ionis)upregulated sodium channel alpha subunit 2 (RogCon Biosciences/Ionis Pharmaceuticals)RCUR-SMP
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionSodium channel protein type II alpha subunit modulators
TargetsSodium channel protein type II alpha subunit
Therapy Area/IndicationsAutistic DisorderEpilepsyCentral Nervous System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRogCon Biosciences
China Registration ClassN/A

Develop Information

Active CompaniesIonis Pharmaceuticals IncRogCon Biosciences
Inactive CompaniesN/A
Active IndicationsAutistic DisorderEpilepsyCentral Nervous System Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A